Key result
Daily administration of 75 mg aspirin for 5 consecutive days decreased maximal collagen-induced platelet aggregation by 80% and 38% at 0.5 and 2.0 µg/mL collagen, respectively.
Why the study?
Does aspirin 75 mg daily affect collagen-induced platelet aggregation in healthy male volunteers?
Does aspirin 75 mg daily affect collagen-induced platelet aggregation in healthy male volunteers?
Effect estimate: 80% and 38% reduction at 0.5 and 2.0 µg/mL collagen
Collagen-induced ex vivo whole blood platelet aggregation is a feasible methodology to evaluate aspirin-drug interactions in healthy volunteers, requiring minimal sample sizes of 9-11 subjects.
Supports feasibility of collagen-induced ex vivo aggregation for aspirin studies in healthy volunteers; extends small-sample methodology but leaves clinical translation open.
Given the broad application of aspirin as antiplatelet drug, availability of standardized methodology to assess potential interaction with any co-medication on platelet aggregation is desired. We characterized the effect of aspirin (ASA) therapy on collagen-induced platelet aggregation in whole blood to define such methodology. Collagen-induced platelet whole blood aggregation was assessed in 6 healthy male volunteers on 2 occasions (Day 1, Day 7) using the Chronolog aggregometer. From Day 2 up to Day 7, subjects received a daily oral dose of 75 mg ASA. The relationship between collagen dose and platelet aggregation response was assessed. On Day 1, maximal aggregation was observed at 1 μg/mL collagen (15.3 ± 4.6 Ω) and higher. Reproducible results were obtained without any indication of intra-subject fluctuations. ASA treatment decreased maximal aggregation by 80% and 38% at 0.5 and 2.0 μg/mL collagen, respectively. Power calculations were performed based on the observed intra-subject variability and demonstrated minimal sample sizes of 9 - 11 subjects for future cross-over ASA-drug interaction studies exploring effects on platelet aggregation, which demonstrates that the proposed collagen-induced ex vivo whole blood platelet aggregation is a feasible methodology to evaluate ASA-drug interactions in healthy volunteers.
No takes yet. Share an insight, caveat, or question.
Kruithof et al. (2015) studied Healthy volunteers (n=6). Aspirin (ASA) vs. Baseline (pre-ASA) was evaluated on Maximal platelet aggregation amplitude induced by collagen (80% and 38% reduction at 0.5 and 2.0 µg/mL collagen). Daily administration of 75 mg aspirin for 5 consecutive days decreased maximal collagen-induced platelet aggregation by 80% and 38% at 0.5 and 2.0 µg/mL collagen, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: